NeuBase Therapeutics, Inc. 3 SEC Filings

Filed On	Filing
01 Sep 2023	Form 3: Symetryx Corp, 10% owner Holds 428,444 shares of Common Stock, Par Value $0.0001 per Share
10 Jan 2022	Form 3: Branning Todd P., Chief Financial Officer No securities owned
05 Jan 2022	Form 3: Ende Eric J, Director No securities owned
25 May 2021	Form 3: Rojas-Caro Sandra, Chief Medical Officer No securities owned
25 May 2021	Form 3: Motesharei Kianoush, See Remarks No securities owned
13 May 2021	Form 3: McDougall Gerald J, Director No securities owned
02 Dec 2020	Form 3: Bradshaw Curt, Chief Scientific Officer No securities owned
28 Jul 2020	Form 3: Mann William Roland, COO No securities owned
16 Jul 2019	Form 3: Miralles Gines Diego, Director No securities owned
16 Jul 2019	Form 3: Prendergast Franklyn G, Director No securities owned
16 Jul 2019	Form 3: Richman Eric I, Director No securities owned
16 Jul 2019	Form 3: Goldstein Dov A Md, Director No securities owned
16 Jul 2019	Form 3: Stephan Dietrich A, Director No securities owned
16 May 2017	Form 3: Ferguson Michael, Director No securities owned
02 Mar 2015	Form 3: Ingerman Avner, Chief Clinical Officer Holds 1,500 shares of Common Stock, par value $0.0001 per share
09 Jan 2015	Form 3: Slakter Jason Scott, Director Holds 425,505 shares of Common Stock, par value $0.0001 per share
01 Jul 2013	Form 3: Hirschman Orin, Director Holds 1,490,059 shares of Common Stock, par value $0.0001 per share
28 Jun 2013	Form 3: Riedhammer Thomas M, Director
24 Jun 2013	Form 3: Greenstein Ira A, Director Holds 266,769 shares of Common Stock, par value $0.0001 per share
24 Jun 2013	Form 3: Almenoff June Sherie, Director

Comments